^
Association details:
| Biomarker: | CEACAM1 overexpression |
|---|---|
| Cancer: | Renal Cell Carcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) + Inlyta (axitinib) (VEGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment in patients with advanced renal cell carcinoma
Published date:
08/18/2020
Excerpt:
Prospectively defined retrospective correlative exploratory analyses tested bio specimens from 52 treatment-naïve patients receiving axitinib and pembrolizumab (starting doses 5 mg twice-daily and 2 mg/kg every 3 weeks). Higher baseline tumor levels of CD8 showed a trend toward longer PFS (hazard ratio [HR] 0.4; P = 0.091). Higher baseline serum levels of CXCL10 (P = 0.0197) and CEACAM1 (P = 0.085) showed a trend toward better ORR and longer PFS, respectively.
DOI:
10.1158/1078-0432.CCR-20-1408
